Re: [100attendees] [100all] Bringing Medications to Singapore

Bill Silverajan <bilhanan.silverajan@tut.fi> Tue, 07 November 2017 06:30 UTC

Return-Path: <bilhanan.silverajan@tut.fi>
X-Original-To: 100attendees@ietfa.amsl.com
Delivered-To: 100attendees@ietfa.amsl.com
Received: from localhost (localhost [127.0.0.1]) by ietfa.amsl.com (Postfix) with ESMTP id AB1E813FAE0 for <100attendees@ietfa.amsl.com>; Mon, 6 Nov 2017 22:30:41 -0800 (PST)
X-Virus-Scanned: amavisd-new at amsl.com
X-Spam-Flag: NO
X-Spam-Score: -0.918
X-Spam-Level:
X-Spam-Status: No, score=-0.918 tagged_above=-999 required=5 tests=[BAYES_00=-1.9, DKIM_SIGNED=0.1, DKIM_VALID=-0.1, GB_H_MEDICATION=1, HTML_MESSAGE=0.001, RCVD_IN_DNSWL_NONE=-0.0001, RCVD_IN_MSPIKE_H4=-0.01, RCVD_IN_MSPIKE_WL=-0.01, URIBL_BLOCKED=0.001] autolearn=no autolearn_force=no
Authentication-Results: ietfa.amsl.com (amavisd-new); dkim=pass (1024-bit key) header.d=tutfi.onmicrosoft.com
Received: from mail.ietf.org ([4.31.198.44]) by localhost (ietfa.amsl.com [127.0.0.1]) (amavisd-new, port 10024) with ESMTP id ZFxaQSiCXtjW for <100attendees@ietfa.amsl.com>; Mon, 6 Nov 2017 22:30:39 -0800 (PST)
Received: from EUR01-DB5-obe.outbound.protection.outlook.com (mail-db5eur01on0132.outbound.protection.outlook.com [104.47.2.132]) (using TLSv1.2 with cipher ECDHE-RSA-AES256-SHA384 (256/256 bits)) (No client certificate requested) by ietfa.amsl.com (Postfix) with ESMTPS id 224F813FAC5 for <100attendees@ietf.org>; Mon, 6 Nov 2017 22:30:38 -0800 (PST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=tutfi.onmicrosoft.com; s=selector1-tut-fi; h=From:Date:Subject:Message-ID:Content-Type:MIME-Version; bh=BMGx0/AoQgrJqx9F9IpbdiHYfn6b9dmkLGlOeokEMtA=; b=QvhmeZ+PegwWotev8jawUiwuGEemg4IiFRv41crPN4+IGJr/JU4UA8ZSI/bJLj9sn9K8yWQmInKFkWKWzORu/G9nhe0oDJTOPHYoC/nX8SqXWWjfp3IE0trUEU8p+fz4uBjZ8grRcb2qyNTw6uRVLcku+v+G4SYjRKm1hfeVeAg=
Authentication-Results: spf=none (sender IP is ) smtp.mailfrom=bilhanan.silverajan@tut.fi;
Received: from dyn-156-43.public.tut.fi (2001:708:310:156:bdcf:d180:52fc:7c28) by AM3PR02MB1076.eurprd02.prod.outlook.com (2a01:111:e400:c405::18) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_CBC_SHA384_P256) id 15.20.197.13; Tue, 7 Nov 2017 06:30:36 +0000
To: 100attendees@ietf.org
References: <150999680842.5393.7575727317009756718.idtracker@ietfa.amsl.com> <DCD28344-CFC6-43F6-AE18-1960E45A8CD0@gmail.com> <807B1623-BD30-4387-9C60-B69466F85A39@gmail.com> <23040.54777.407599.952065@tale.kendall.corp.akamai.com> <0bddc785-94a5-b1d1-d61e-a90b2958f5b2@isc.org> <CACknUNUqb-L9Qr6cFoifEMhPB6fQxTPVeXPVe+B5ZxEPnwWOkw@mail.gmail.com> <4bd5f8cd-2617-0afb-0d2f-0547f2cd7c44@isc.org> <08B1FBC7-31F6-4A4F-83B3-87D8A4ACA783@ogre.com> <07EA19A1-BAD5-458E-8E6D-CDA3E0910D5B@cisco.com> <6e1f9501-316d-ff45-f009-611a3c596b5b@fastly.com>
From: Bill Silverajan <bilhanan.silverajan@tut.fi>
Message-ID: <d4f1ab1c-2f57-cf08-3c86-b634eed34c28@tut.fi>
Date: Tue, 7 Nov 2017 08:30:29 +0200
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10.11; rv:52.0) Gecko/20100101 Thunderbird/52.4.0
MIME-Version: 1.0
In-Reply-To: <6e1f9501-316d-ff45-f009-611a3c596b5b@fastly.com>
Content-Type: multipart/alternative; boundary="------------054B9D9AF6B2F9E0CD14769A"
Content-Language: en-US
X-Originating-IP: [2001:708:310:156:bdcf:d180:52fc:7c28]
X-ClientProxiedBy: HE1P191CA0020.EURP191.PROD.OUTLOOK.COM (2603:10a6:3:cf::30) To AM3PR02MB1076.eurprd02.prod.outlook.com (2a01:111:e400:c405::18)
X-MS-PublicTrafficType: Email
X-MS-Office365-Filtering-Correlation-Id: 5f1df054-6034-4a2d-57e6-08d525a90e5c
X-Microsoft-Antispam: UriScan:; BCL:0; PCL:0; RULEID:(22001)(4534020)(4602075)(4627115)(201703031133081)(201702281549075)(2017052603199); SRVR:AM3PR02MB1076;
X-Microsoft-Exchange-Diagnostics: 1; AM3PR02MB1076; 3:7qYKtV7GZ2h3KgUDrX6p6m+wNM0op95M7qTH33eornsRKFfN0GV3Zl/EK0jIrmtzwDf1zvyInx6zqDn/V1Acox8R2yxlDLZNU7OyjATz9gwvU461njCNlsrFd2qS0b/nACs6y/CMjlYLsuOzbLETHq8EBoOxggVWIsCHwnp8kW1han1I2pfnOFnvQ8qPAxDL3Ndzc6yPlNynd21VoVj7lfxBKO2rto2648rUeOB2Z40vAIsMK+9gJYlvCY52kiLV; 25:GfrvIUyLivkV5kQoCLUszDQNx++8+aNsyTtSuUO7x4DFcanCWDe28oh4vmCER4odt70SljtB3tzHLdEUd3IKbqrRfvwI9E9+uhnEgVvnOzKtChNouEUDQV81BiIQa14Ei1ScT6ZodFV9mg9y9QJ/lkovlDps2mKV0kCx1rojVam8m4JUiib9ufIV8bPmBs38u+nMahl7eN8rI2QJ3uZrfBMc4wiJj0id2900Ba7zZAauqTGgwdTMBOHioEzOf7z6x7L3FNrWnIE75F7n4yWVx09xipikPNUZNF3FhqoHHgC/Cwf11LQHSCupHmJ6u0N26G8Hxskh1zGcpGQIMGm/Sg==; 31:fyf1zX0+BMtbvKjlica8hF4Dguf0RaPuwenjEb90TD16sLNWpbUSDHWD30kzsgGs/0fs076O3tphCI5TcBkRbZcP3j1w1LsE9cJLpa7jcP71pqd+MiGBOngcfEbIrDAcZaHhXS6ocoY0JxbkN2uTvt3QNM1cphg6UBl8I7z4gDFzemTuEzwkNXtpw6yfbfSNt/krtJp89jeENFhVhqQgofg+wGkDD+hJ/2Vp9QrmS3c=
X-MS-TrafficTypeDiagnostic: AM3PR02MB1076:
X-Microsoft-Exchange-Diagnostics: 1; AM3PR02MB1076; 20:+HJjh0gUGYUQmbbvWAhDSeis/FxqBCPbaz5/BULxpnUqhbMYLy7UPzu6/qRafPeidtMv1mY/NmPjqbgaLDlQIl61iQvjQwe94KmLkHiR1qBk4D/Qlhgs3Vis367D0UgJNJkeyn32MeEXBSxqxU6z3HSx7R9m+9ZEtC5NZ+Uq6NgwE5bSKa1apGnYKj1eGoZiq1OmvYRB2p2wxS6KQC/NgiZWbHHQbo+RQx+tD+ZNkn3UtctnWWwQreDjtyqzH+iT; 4:Y/BhsyzmtAAHRzV1j39pYenP5KdKkpnZSsodo5UlAkDt7aicYC9Rw7EH7r/garsk1rPSPRhFDN5h9lW/Rho7vJp2TbACPI8mE50f1UJCQIY9lFl9B8HtON1G45WJGebBzfRsO7nTKwagtePaHMvtjle7gwY6eDn5igs3CDYZ0FlQfO+CASO1bg+2ECJ9yEiNm8q8wISMBoRrgY86MVOc4scYuMrZBex8dMh8zls4sW/Y0i0kboXP1k45+dfGWnawz2lRD01nz6RKdI4mm4pUvyX80Vl+yvxSxBoOW9/6hwjf9P+qwAMcv/EF7iMGHSFx
X-Exchange-Antispam-Report-Test: UriScan:(192374486261705);
X-Microsoft-Antispam-PRVS: <AM3PR02MB1076FED35F538410B32DDCC89C510@AM3PR02MB1076.eurprd02.prod.outlook.com>
X-Exchange-Antispam-Report-CFA-Test: BCL:0; PCL:0; RULEID:(100000700101)(100105000095)(100000701101)(100105300095)(100000702101)(100105100095)(6040450)(2401047)(8121501046)(5005006)(3002001)(93006095)(93001095)(10201501046)(3231021)(100000703101)(100105400095)(6041248)(20161123555025)(20161123558100)(20161123560025)(20161123564025)(20161123562025)(201703131423075)(201702281529075)(201702281528075)(201703061421075)(201703061406153)(6072148)(201708071742011)(100000704101)(100105200095)(100000705101)(100105500095); SRVR:AM3PR02MB1076; BCL:0; PCL:0; RULEID:(100000800101)(100110000095)(100000801101)(100110300095)(100000802101)(100110100095)(100000803101)(100110400095)(100000804101)(100110200095)(100000805101)(100110500095); SRVR:AM3PR02MB1076;
X-Forefront-PRVS: 0484063412
X-Forefront-Antispam-Report: SFV:NSPM; SFS:(10019020)(376002)(346002)(199003)(189002)(24454002)(6246003)(54356999)(76176999)(50986999)(105586002)(65826007)(2351001)(33646002)(93886005)(54896002)(6306002)(236005)(53416004)(2361001)(106356001)(65806001)(65956001)(229853002)(6916009)(478600001)(5660300001)(101416001)(84326002)(2950100002)(36756003)(7736002)(6666003)(69596002)(53936002)(97736004)(8936002)(68736007)(83506002)(74482002)(786003)(37036004)(316002)(58126008)(16586007)(8676002)(2906002)(81166006)(81156014)(25786009)(189998001)(86362001)(6486002)(31686004)(6116002)(966005)(606006)(64126003)(31696002)(53546010)(155363001)(359044002); DIR:OUT; SFP:1102; SCL:1; SRVR:AM3PR02MB1076; H:dyn-156-43.public.tut.fi; FPR:; SPF:None; PTR:InfoNoRecords; A:1; MX:1; LANG:en;
Received-SPF: None (protection.outlook.com: tut.fi does not designate permitted sender hosts)
X-Microsoft-Exchange-Diagnostics: =?us-ascii?Q?1; AM3PR02MB1076; 23:t8al3/aJfE3x5zeliC5D6e3TZVMJ9HaiNzQCRcm1s?= =?us-ascii?Q?Z/Uh7rV6G5t47Vf+T7bmFM+Tfka5LU6Y758IXhNjouLkRgOT+FN6gTKAa6Hn?= =?us-ascii?Q?AV1TIeO2RMoWH1jblbBK3vEppdmO44HBCS+BFm+izQPWg/N/xkTnhWagHZCY?= =?us-ascii?Q?M+WRr7id9vlb0IuPM45clmiTEH8T4zj4i3gA35jG5SoUg07K0uP2sQ0hVKp1?= =?us-ascii?Q?7R0kJcQLrfcLKOXXuVztjOP4obnSHQc8W955qkX+ijlYhETJHH+Ix7RKALdN?= =?us-ascii?Q?TdaBv5jDjZcNKsSLIUNeusHh+FPIV0vQxprU8hQouSiAjzyCsTjB+h8KFvY1?= =?us-ascii?Q?74RWQ4u3W3xukBl1u7SG6EkILZFOnaBm8qaXLynugSEc9p82sPbMC8Mxxha8?= =?us-ascii?Q?cyBLCDH1YlNihLJF+FYxv8qgjk5EGzHOXirlPIA+cC04dmFJB9iZZvAz6sPg?= =?us-ascii?Q?K4aTtE8iw2vMzzrZ4Rg02VLM+8qUC1G3N8jZerVRViy9UcNLJj/i73VUxlOt?= =?us-ascii?Q?Y0wTIFO/dorO28JStz1LMAWKybahvoM3qGimQwm8wbqrBIMFwdZq8id5PFdh?= =?us-ascii?Q?VpYmxPS/TetILrjqTa067iwflwECw7u6XvuvS85w0IfZOIj7xkMgemXp5yAo?= =?us-ascii?Q?krp9ygyMLnlOsaHsp6ZggCpziKHiKayQ/zRRb4grU0I82SrLCSyYYSiYbL+3?= =?us-ascii?Q?AiPnVy/a+a8bfNuj3aFSYN5g+4FWK2etj6ZZry2deWdxlbFFBup6MkVPkexw?= =?us-ascii?Q?hcboTKPELiLgpnMKyJeP4jOkbvSKWFitE9akdFmPaWW79QQXJWwQwtqCYMCP?= =?us-ascii?Q?Hm9n3cDpr8ZiiTyXGD6Iq48MY8PG3g5ZOTUlhTOc9EhXtzEXzzFM23zAoHWR?= =?us-ascii?Q?7JzBNWZ3xJtmP1+z++RPjOUMPOTrwtS0QQcyL2bZvxRamRb87qNGFx23PFiA?= =?us-ascii?Q?ge98c4G0z1MWGx4hm959zNAsUs0pZRoF10neE/Jh40LJ9bQ7G2V4jPhMiQg0?= =?us-ascii?Q?eQ45GiRKQ/9Fb+o66JrmqmncYbx1KxEz1c62kYT8EE2LPs/x/RmfQeXXnot9?= =?us-ascii?Q?nJ+GWURKiKoYVV10znH9qjcPhHio2MD+ezLXurZafH3xlS0yhy707o/hcGHE?= =?us-ascii?Q?G9Q1X34EDNO80QfDINapqhG7hcoaMrnhaX+HLyHb2iPb27gE+AMltVKfyh18?= =?us-ascii?Q?EbVlheG3haiLdRk1wsjjFj5RqoyRAae+ZHEroDxF/W0AyV2WxLaIwUYzuXD2?= =?us-ascii?Q?kmdq5QLlxwFDiyJRGh+d7+iWbktNcNNO01k/JUQTYVxGAkh9c17FXNouQr+7?= =?us-ascii?Q?kuy3XteVrnTYP66+EQyWnpyki9GpV/bQG2oROaH8fSKq7kd5kh6yPt2gq2Ms?= =?us-ascii?Q?tlG0M4Wk8ONuKiFk7RxYjArNQU=3D?=
X-Microsoft-Exchange-Diagnostics: 1; AM3PR02MB1076; 6:lPiELCDaHQFcxzlinRxateznlhRjhVM3CAl74VAdcGVSC2q8T9MPznvWLGW6fwySuDZTnwlugmabHRQq/sKnoio79U4apTy0sw9UwkXtXPlbeYSBVINVfYDCQ5aFseV+Kd6n3rd1KJVA+a0TZu6uD0YwV3w/ZWsCPTfJh8RV+sJ++lwEL8ITRNuY8Nc5DTCxtqHwCqj/HUQHWwajI/x7EmNxSfjj2TaTDS614b7+TC7endSou1eFUbwcd2KPC1RIDuY79WHktFRCmQQr2j7ARw0h3flkMZZFQ1gMrl28L8apZ+AVK9EB4EXheq1Rmoh85PzByrw3fA8PKlTCK2EgowPzGA9HDzP/RACtlrjO4lo=; 5:Y7+NayczA1fwqmdXJdfx1fXNh5qR3RxVDIyNWbNMCQS893ypE7aEnlkJn47/quHkCZ2sz+Y9ld6LsxOPE4c9lyKTJpfjEXHTJAceOGqW08V9ZMLDRD7CggW5rmQVb0uzYQ2I8itcLCw+8XJO0Ci245DbZ6CIrB3qkQ3QCBKFTmY=; 24:8czJ6ycCAnso9Q2xVF2Wrl0l/7VWKuwTGefnyvGD9JipKoPJ2XzCb1hO194KlFvJk9sVa7Vof3PyqvgDabDrAH6KVQFXpLDjhCo65oLNLI8=; 7:YNlVRnaQLqoA1xC1kB62cI9rWwPv6Z/xirX1dZyCWfDpz/5EUrVvKt7S3n6IvM9MKL1K6yBVBJ05yIYKLjRauNyJ3rbfB5gjycyIyOBJ9JeMmM2Zmjp62058zOUlp4cUoVR2vW0djzOgr8ePtll4C4O1iA5mZWrWLjiA8TSg40xk/nGphaBSfCyschXfUfwv6tjekyavtYmFjfHY8Kq0omgK5Vir5B8ME4QnUJR/sjDOHT9Pr9IiNK5+/bsZtvrN
SpamDiagnosticOutput: 1:99
SpamDiagnosticMetadata: NSPM
X-OriginatorOrg: tut.fi
X-MS-Exchange-CrossTenant-OriginalArrivalTime: 07 Nov 2017 06:30:36.2176 (UTC)
X-MS-Exchange-CrossTenant-Network-Message-Id: 5f1df054-6034-4a2d-57e6-08d525a90e5c
X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted
X-MS-Exchange-CrossTenant-Id: 271a0e2b-2a07-4d45-840b-ca860972fd60
X-MS-Exchange-Transport-CrossTenantHeadersStamped: AM3PR02MB1076
Archived-At: <https://mailarchive.ietf.org/arch/msg/100attendees/RHHugZW-hxkllF-adcsV2Syu2AA>
Subject: Re: [100attendees] [100all] Bringing Medications to Singapore
X-BeenThere: 100attendees@ietf.org
X-Mailman-Version: 2.1.22
Precedence: list
List-Id: "Mailing list of IETF 100 attendees that have opted in on this list." <100attendees.ietf.org>
List-Unsubscribe: <https://www.ietf.org/mailman/options/100attendees>, <mailto:100attendees-request@ietf.org?subject=unsubscribe>
List-Archive: <https://mailarchive.ietf.org/arch/browse/100attendees/>
List-Post: <mailto:100attendees@ietf.org>
List-Help: <mailto:100attendees-request@ietf.org?subject=help>
List-Subscribe: <https://www.ietf.org/mailman/listinfo/100attendees>, <mailto:100attendees-request@ietf.org?subject=subscribe>
X-List-Received-Date: Tue, 07 Nov 2017 06:30:42 -0000

While I don't reside in Singapore, I'm Singaporean and I visit home 
often enough to be able to provide some pointers to some of the concerns 
raised. Sorry for being late to the party :-)

My visits to Singapore last a couple of weeks at a time, and when I 
travel with my children, I tend to err on the side of caution when it 
comes to medication.

In the past 5 or 6 years, I've not needed to declare any medications for 
long-term asthma (which include cortesoids, tablets, inhalers), 
painkillers, antihistamines, aspirins, anticongestants, lactobacillus 
tablets and cough syrups. When family comes over to visit me, they've 
not needed to declare any long-term medication for heart illnesses or 
diabetes either.

As a precaution, I do, however, often carry a doctor's statement about 
the meds (in case verification is required security or border control at 
any country, including Singapore), but I've never needed to produce it 
anywhere.

Regards,
Bill

On 07/11/17 03:53, Melinda Shore wrote:
> On 11/6/17 4:32 PM, Hrvoje (Harry) Dogan (hrdogan) wrote:> It’s really
> awesome when you learn about the country from Wikipedia
>> articles.
> I'm not sure it's a great idea to be snide about this.  When
> someone is working from very incomplete information, as we
> tend to be when considering a country we've never visited and
> know little about, it's difficult to know which laws are
> heavily enforced, what the culture is around certain things,
> etc.  So it would be very cool if you'd cut people some slack
> when they're asking what's okay and what's not.
>
> Melinda
>
>
>
> _______________________________________________
> 100attendees mailing list
> 100attendees@ietf.org
> https://www.ietf.org/mailman/listinfo/100attendees